Medical News, Health News Latest, Medical News Today - Medical Dialogues |

Premarket approval application for Skinvive by Juvederm for neck lines reduction under USFDA review: Abbvie Allergan Aesthetics

Irvine: AbbVie's Allergan Aesthetics has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM to reduce neck lines for the improvement of neck appearance.

Irvine: AbbVie's Allergan Aesthetics has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM to reduce neck lines for the improvement of neck appearance.

SKINVIVE by JUVÉDERM is currently approved in the U.S. to improve skin smoothness of the cheeks in adults over the age of 21.

"SKINVIVE by JUVÉDERM is an injectable version of hyaluronic acid, a naturally occurring molecule found in the skin and important for skin hydration," said Darin Messina, Ph.D., senior vice president, aesthetics R&D, AbbVie. "The submission of SKINVIVE by JUVÉDERM to treat neck lines demonstrates our continued focus on developing new indications for comprehensive lower face and neck treatment as part of our market-leading portfolio of products, including BOTOX Cosmetic and SkinMedica."

Neck appearance is a top concern among people seeking aesthetic treatment, with millions of consumers considering professionally administered treatments to address their neck concerns. SKINVIVE by JUVÉDERM could offer hyaluronic acid injectable that aims to reduce neck lines to improve neck appearance.

The sPMA submission is supported by data from a multicenter, evaluator-blinded, randomized controlled study evaluating the safety and effectiveness of SKINVIVE by JUVÉDERM in adults with moderate to severe horizontal neck lines seeking improvement in neck appearance. All primary and secondary endpoints were met. Based on investigator assessment of horizontal neck lines, 80% of patients treated with SKINVIVE by JUVÉDERM achieved at least a 1-grade improvement at month 1. Nearly 90% of patients treated with SKINVIVE by JUVÉDERM reported improvement in neck appearance at month 1 as assessed by the Global Aesthetic Improvement Scale. Patients treated with SKINVIVE by JUVÉDERM reported being significantly less bothered with the overall appearance of their neck following treatment as measured by the FACE-Q questionnaire, while patients in the control group demonstrated no significant change. Treatment-emergent adverse events for SKINVIVE by JUVÉDERM were mild in severity and consistent with known safety profile. Additional data from the clinical study will be submitted for presentation at a future medical congress and for publication.

"Patients express frustration about the visible changes in their neck due to aging and sun exposure and seek non-surgical treatment options to address them," said Jeanine Downie, MD, FAAD, board-certified dermatologist and clinical investigator. "SKINVIVE by JUVÉDERM may offer another tool for patients exploring their aesthetics treatment journey beyond the face."

3 months 3 weeks ago

News,Dermatology,Dermatology News,Industry,Pharma News,Latest Industry News

KFF Health News

‘MAHA Report’ Calls for Fighting Chronic Disease, but Trump and Kennedy Have Yanked Funding

The Trump administration has declared that it will aggressively combat chronic disease in America.

Yet in its feverish purge of federal health programs, it has proposed eliminating the National Center for Chronic Disease Prevention and Health Promotion and its annual funding of $1.4 billion.

The Trump administration has declared that it will aggressively combat chronic disease in America.

Yet in its feverish purge of federal health programs, it has proposed eliminating the National Center for Chronic Disease Prevention and Health Promotion and its annual funding of $1.4 billion.

That’s one of many disconnects between what the administration says about health — notably, in the “MAHA Report” that President Donald Trump recently presented at the White House — and what it’s actually doing, scientists and public health advocates say.

Among other contradictions:

  • The report says more research is needed on health-related topics such as chronic diseases and the cumulative effects of chemicals in the environment. But the Trump administration’s mass cancellation of federal research grants to scientists at universities, including Harvard, has derailed studies on those subjects.
  • The report denounces industry-funded research on chemicals and health as widespread and unreliable. But the administration is seeking to cut government funding that could serve as a counterweight.
  • The report calls for “fearless gold-standard science.” But the administration has sowed widespread fear in the scientific world that it is out to stifle or skew research that challenges its desired conclusions.

“There are many inconsistencies between rhetoric and action,” said Alonzo Plough, chief science officer at the Robert Wood Johnson Foundation, a philanthropy focused on health.

The report, a cornerstone of President Donald Trump’s “Make America Healthy Again” agenda, was issued by a commission that includes Secretary of Health and Human Services Robert F. Kennedy Jr. and other top administration officials.

News organizations found that it footnoted nonexistent sources and contained signs that it was produced with help from artificial intelligence. White House Press Secretary Karoline Leavitt described the problems as “formatting issues,” and the administration revised the report.

Trump ordered the report to assess causes of a “childhood chronic disease crisis.” His commission is now working on a plan of action.

Spokespeople for the White House and Department of Health and Human Services did not respond to questions for this article.

Studies Derailed

The MAHA report says environmental chemicals may pose risks to children’s health. Citing the National Institutes of Health, it said there’s a “need for continued studies from the public and private sectors, especially the NIH, to better understand the cumulative load of multiple exposures and how it may impact children’s health.”

Meanwhile, the administration has cut funding for related studies.

For example, in 2020 the Environmental Protection Agency asked scientists to propose ways of researching children’s exposure to chemicals from soil and dust. It said that, for kids ages 6 months to 6 years, ingesting particulates — by putting their hands on the ground or floor then in their mouths — could be a significant means of exposure to contaminants such as herbicides, pesticides, and a group of chemicals known as PFAS.

One of the grants — for almost $1.4 million over several years — went to a team of scientists at Johns Hopkins University and the University of California-San Francisco. Researchers gained permission to collect samples from people’s homes, including dust and diapers.

But, beyond a small test run, they didn’t get to analyze the urine and stool samples because the grant was terminated this spring, said study leader Keeve Nachman, a professor of environmental health and engineering at Hopkins.

“The objectives of the award are no longer consistent with EPA funding priorities,” the agency said in a May 10 termination notice.

Another EPA solicitation from 2020 addressed many of the issues the MAHA report highlighted: cumulative exposures to chemicals and developmental problems such as attention-deficit/hyperactivity disorder, obesity, anxiety, and depression. One of the resulting grants funded the Center for Early Life Exposures and Neurotoxicity at the University of North Carolina-Chapel Hill. That grant was ended weeks early in May, said the center’s director, Stephanie Engel, a UNC professor of epidemiology.

In a statement, EPA press secretary Brigit Hirsch said the agency “is continuing to invest in research and labs to advance the mission of protecting human health and the environment.” Due to an agency reorganization, “the way these grants are administered will be different going forward,” said Hirsch, who did not otherwise answer questions about specific grants.

In its battle with Harvard, the Trump administration has stopped paying for research the NIH had commissioned on topics such as how autism might be related to paternal exposure to air pollution.

The loss of millions of dollars of NIH funding has also undermined data-gathering for long-term research on chronic diseases, Harvard researchers said. A series of projects with names like Nurses’ Health Study II and Nurses’ Health Study 3 have been tracking thousands of people for decades and aimed to keep tracking them as long as possible as well as enrolling new participants, even across generations.

The work has included periodically surveying participants — mainly nurses and other health professionals who enrolled to support science — and collecting biological samples such as blood, urine, stool, or toenail clippings.

Researchers studying health problems such as autism, ADHD, or cancer could tap the data and samples to trace potential contributing factors, said Francine Laden, an environmental epidemiologist at Harvard’s T.H. Chan School of Public Health. The information could retrospectively reveal exposures before people were born — when they were still in utero — and exposures their parents experienced before they were conceived.

Harvard expected that some of the grants wouldn’t be renewed, but the Trump administration brought ongoing funding to an abrupt end, said Walter Willett, a professor of epidemiology and nutrition at the Chan school.

As a result, researchers are scrambling to find money to keep following more than 200,000 people who enrolled in studies beginning in the 1980s — including children of participants who are now adults themselves — and to preserve about 2 million samples, Willett said.

“So now our ability to do exactly what the administration wants to do is jeopardized,” said Jorge Chavarro, a professor of nutrition and epidemiology at the Chan school. “And there’s not an equivalent resource. It’s not like you can magically recreate these resources without having to wait 20 or 30 years to be able to answer the questions” that the Trump administration “wants answered now.”

Over the past few months, the administration has fired or pushed out almost 5,000 NIH employees, blocked almost $3 billion in grant funding from being awarded, and terminated almost 2,500 grants totaling almost $5 billion, said Sen. Patty Murray (D-Wash.), vice chair of the Senate Appropriations Committee, at a June 10 hearing on the NIH budget.

In addition, research institutions have been waiting months to receive money under grants they’ve already been awarded, Murray said.

In canceling hundreds of grants with race, gender, or sexuality dimensions, the administration engaged in blatant discrimination, a federal judge ruled on June 16.

Cutting Funding

After issuing the MAHA report, the administration published budget proposals to cut funding for the NIH by $17.0 billion, or 38%, the Centers for Disease Control and Prevention by $550 million, or 12%, and the EPA by $5 billion, or 54%.

“This budget reflects the President’s vision of making Americans the healthiest in the world while achieving his goal of transforming the bureaucracy,” the HHS “Budget in Brief” document says. Elements of Trump’s proposed budget for the 2026 fiscal year clash with priorities laid out in the MAHA report.

Kennedy has cited diabetes as part of a crisis in children’s health. The $1.4 billion unit the White House has proposed to eliminate at the CDC — the National Center for Chronic Disease Prevention and Health Promotion — has housed a program to track diabetes in children, adolescents, and young adults.

“To say that you want to focus on chronic diseases” and then “to, for all practical purposes, eliminate the entity at the Centers for Disease Control and Prevention which does chronic diseases,” said Georges Benjamin, executive director of the American Public Health Association, “obviously doesn’t make a lot of sense.”

In a May letter, Office of Management and Budget Director Russell Vought listed the chronic disease center as “duplicative, DEI, or simply unnecessary,” using an abbreviation for diversity, equity, and inclusion programs.

Within the NIH, the White House has proposed cutting $320 million from the National Institute of Environmental Health Sciences, a reduction of 35%. That unit funds or conducts a wide array of research on issues such as chronic disease.

Trump’s budget proposes spending $500 million “to tackle priority activities to Make America Healthy Again,” including $260 million for his new Administration for a Healthy America to address the “chronic illness epidemic.”

Ceding Ground to Industry

The MAHA report argues that corporate influence has compromised government agencies and public health through “corporate capture.”

It alleges that most research on chronic childhood diseases is funded by the food, pharmaceutical, and chemical industries, as well as special interest organizations and professional associations. It says, for example, that a “significant portion of environmental toxicology and epidemiology studies are conducted by private corporations,” including pesticide manufacturers, and it cites “potential biases in industry-funded research.”

It’s “self-evident that cutbacks in federal funding leave the field open to the very corporate funding RFK has decried,” said Peter Lurie, president of the Center for Science in the Public Interest, a watchdog group focused on food and health.

Lurie shared the report’s concern about industry-funded research but said ceding ground to industry won’t help. “Industry will tend to fund those studies that look to them like they will yield results beneficial to industry,” he said.

In search of new funding sources, Harvard’s school of public health “is now ramping up targeted outreach to potential corporate partners, with careful review to ensure the science meets the highest standards of research integrity,” Andrea Baccarelli, dean of the school’s faculty, wrote in a June 11 letter to students, faculty, and others.

“It’s just simple math that if you devastate governmental funding by tens of billions of dollars, then the percentage of industry funding dollars will go up,” said Plough, who is also a clinical professor at the University of Washington School of Public Health.

“So therefore, what they claim to fear more,” he said, will “become even more influential.”

The MAHA report says “the U.S. government is committed to fostering radical transparency and gold-standard science.”

But many scientists and other scholars see the Trump administration waging a war on science that conflicts with its agenda.

In March, members of the National Academies of Sciences, Engineering, and Medicine accused the administration of “destroying” scientific independence, “engaging in censorship,” and “pressuring researchers to alter or abandon their work on ideological grounds.”

In May, NIH employees wrote that the administration was politicizing research — for example, by halting or censoring work on health disparities, health impacts of climate change, gender identity, and immunizations.

Recent comments by Kennedy pose another threat to transparency, researchers and health advocates say.

Kennedy said on a podcast that he would probably create in-house government journals and stop NIH scientists from publishing their research in The Lancet, The New England Journal of Medicine, The Journal of the American Medical Association, and others.

Creating new government outlets for research would be a plus, said Dariush Mozaffarian, director of the Food is Medicine Institute at the Friedman School of Nutrition Science and Policy at Tufts University.

But confining government scientists to government journals, he said, “would be a disaster” and “would basically amount to censorship.”

“That’s just not a good idea for science,” Mozaffarian said.

We’d like to speak with current and former personnel from the Department of Health and Human Services or its component agencies who believe the public should understand the impact of what’s happening within the federal health bureaucracy. Please message KFF Health News on Signal at (415) 519-8778 or get in touch here.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

USE OUR CONTENT

This story can be republished for free (details).

3 months 4 weeks ago

Health Industry, Agency Watch, CDC, Chronic Disease Care, Environmental Health, HHS, NIH, Trump Administration

KFF Health News

Con el verano hay más mosquitos y, temen oficiales, más casos de dengue

Con el verano marcando el comienzo de la temporada alta de mosquitos, autoridades sanitarias y de control de vectores se preparan para la posibilidad de otro año con tasas históricas de dengue.

Con el verano marcando el comienzo de la temporada alta de mosquitos, autoridades sanitarias y de control de vectores se preparan para la posibilidad de otro año con tasas históricas de dengue. Y con el cambio climático, la falta de una vacuna eficaz y los recortes federales en la investigación, les preocupa que la enfermedad se vuelva endémica en una franja más amplia de Norteamérica.

El año pasado se reportaron alrededor de 3.700 nuevas infecciones por dengue en Estados Unidos, frente a las 2.050 de 2023, según los Centros para el Control y Prevención de Enfermedades (CDC). Todos los casos de 2024 se adquirieron en el extranjero, excepto 105 contraídos en California, Florida o Texas. Los CDC emitieron una alerta sanitaria en marzo advirtiendo sobre el riesgo continuo de infección por dengue.

"Creo que el dengue ha llegado para quedarse", declaró Michael Ben-Aderet, especialista en enfermedades infecciosas y director médico asociado de epidemiología hospitalaria del Cedars-Sinai de Los Ángeles, sobre la posibilidad de que el dengue se convierta en la nueva normalidad en el país. "Estos mosquitos no se irán a ninguna parte".

El dengue es endémico —una etiqueta que las autoridades de salud pública asignan cuando las enfermedades aparecen de forma constante en una región— en muchas zonas más cálidas del mundo, como Latinoamérica, India y el sudeste asiático. Los casos de dengue aumentaron notablemente el año pasado en muchos de esos lugares, especialmente en Centro y Sur América.

La enfermedad, que puede propagarse por la picadura de mosquitos Aedes que portan el virus, no fue común en Estados Unidos continental durante gran parte del siglo pasado. Actualmente, la mayoría de los casos de dengue adquiridos localmente (es decir, no relacionados con viajes) en el país se registran en Puerto Rico, donde se registró un fuerte aumento en 2024, lo que desencadenó una emergencia de salud pública local.

La mayoría de las personas que desarrollan dengue no se enferman. Sin embargo, en algunas, los síntomas son graves: sangrado por la nariz o la boca, dolor de estómago intenso, vómitos e hinchazón. En ocasiones, el dengue causa la muerte.

California ofrece un caso centinela sobre la propagación del dengue en el país. Hace 25 años, no se conocía la presencia de los mosquitos Aedes aegypti y Aedes albopictus, que transmiten el dengue, en el estado. Actualmente, se encuentran en 25 condados y más de 400 ciudades y comunidades no incorporadas, principalmente en el sur de California y en el Valle Central.

La propagación de los mosquitos es preocupante porque su presencia aumenta la probabilidad de transmisión de enfermedades, afirmó Steve Abshier, presidente de la Mosquito and Vector Control Association of California.

Entre 2016 y 2022, se registró un promedio de 136 nuevos casos de dengue al año en California, cada uno de los cuales probablemente traído al estado por alguien que viajó y se infectó en otro lugar. En 2023, se registraron alrededor de 250 casos nuevos, incluyendo dos adquiridos localmente.

En 2024, California registró 725 nuevos casos de dengue, incluyendo 18 adquiridos localmente, según datos estatales.

El cambio climático podría contribuir al aumento de la población de mosquitos Aedes, afirmó Ben-Aderet. Estos mosquitos sobreviven mejor en zonas urbanas cálidas, y suelen picar durante el día. Las infecciones de transmisión local suelen ocurrir cuando alguien contrae dengue durante un viaje, regresa a casa y lo pica un mosquito Aedes que, a su vez, pica e infecta a otra persona.

"Se han propagado rápidamente por toda California", explicó Ben-Aderet.

El dengue representa un desafío para muchos médicos de atención primaria que nunca lo han visto. Ben-Aderet dijo que los médicos que sospechan dengue deben obtener un historial de viaje detallado de sus pacientes, pero confirmar el diagnóstico no siempre es rápido.

"No existe una prueba sencilla para detectarlo", afirmó. "La única prueba que tenemos para el dengue son las pruebas de anticuerpos". Agregó que "la mayoría de los laboratorios probablemente no lo estén comercializando, por lo que suele ser una prueba que se debe analizar en otra instalación. Por lo tanto, es fundamental sospechar que alguien tiene dengue".

Las mejores prácticas para evitar el dengue incluyen eliminar cualquier agua estancada en una propiedad, aunque sea poca, y usar repelente de mosquitos, dijo Abshier. Limitar la actividad al atardecer y al amanecer, cuando los mosquitos pican con mayor frecuencia, también puede ayudar.

Los esfuerzos para combatir el dengue en California se complicaron aún más este año después de que los incendios forestales arrasaran Los Ángeles.

Los incendios ocurrieron en una zona de alta incidencia de enfermedades transmitidas por mosquitos. Funcionarios del San Gabriel Valley Mosquito and Vector Control District han trabajado durante meses para tratar más de 1.400 piscinas sin mantenimiento que quedaron tras el incendio, eliminando así posibles criaderos de mosquitos.

Estos oficiales han utilizado recursos locales y estatales para tratar las piscinas, dijo Anais Medina Díaz, vocera del distrito. Han solicitado un reembolso a la Agencia Federal para el Manejo de Emergencias (FEMA), que históricamente no ha financiado las iniciativas de control de vectores luego de incendios forestales.

En California, las agencias de control de vectores suelen financiarse principalmente con impuestos y tasas locales que pagan los propietarios.

Algunos funcionarios están implementando el novedoso método de liberar mosquitos Aedes esterilizados para reducir el problema. Eso puede resultar eficaz, pero implementar el método en un gran número de áreas sería costoso y requeriría un esfuerzo masivo a nivel estatal, dijo Abshier.

Mientras tanto, el gobierno federal está reduciendo sus intervenciones: varios medios han informado que los Institutos Nacionales de Salud dejarán de financiar nuevas investigaciones relacionadas con el cambio climático, que podrían incluir trabajos sobre el dengue.

Este año, las tasas de dengue reportadas en gran parte del continente americano han disminuido significativamente desde 2024. Sin embargo, es probable que la tendencia en Estados Unidos no se esclarezca hasta finales de año, después que termine la temporada de mosquitos de verano.

Los investigadores de salud y control de vectores no están seguros de la gravedad de la situación en California.

Algunos afirman que podría haber brotes limitados, mientras que otros predicen que el dengue podría empeorar mucho. Sujan Shresta, profesor e investigador de enfermedades infecciosas en el Instituto de Inmunología de La Jolla, señaló que otros lugares, como Nepal, experimentaron relativamente pocos casos de dengue en el pasado reciente, pero ahora se registran brotes grandes con regularidad.

Existe una vacuna para niños, pero está siendo discontinuada debido a la falta de demanda mundial. Otras dos vacunas no están disponibles en Estados Unidos. El laboratorio de Shresta trabaja arduamente en una vacuna eficaz y segura contra el dengue. Espera publicar los resultados de las pruebas en animales en aproximadamente un año; si son positivos, los ensayos en humanos podrían ser posibles en unos dos años.

"Si no hay una buena vacuna ni buenos antivirales, este será un país endémico para dengue", afirmó.

Phillip Reese es especialista en reportaje de datos y profesor asociado de Periodismo en la Universidad Estatal de California-Sacramento.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

USE OUR CONTENT

This story can be republished for free (details).

3 months 4 weeks ago

Global Health Watch, Noticias En Español, Public Health, States, california, Florida, Latinos, texas

KFF Health News

As Mosquito Season Peaks, Officials Brace for New Normal of Dengue Cases

As summer ushers in peak mosquito season, health and vector control officials are bracing for the possibility of another year of historic rates of dengue.

As summer ushers in peak mosquito season, health and vector control officials are bracing for the possibility of another year of historic rates of dengue. And with climate change, the lack of an effective vaccine, and federal research cuts, they worry the disease will become endemic to a larger swath of North America.

About 3,700 new dengue infections were reported last year in the contiguous United States, up from about 2,050 in 2023, according to the Centers for Disease Control and Prevention. All of last year’s cases were acquired abroad, except for 105 cases contracted in California, Florida, or Texas. The CDC issued a health alert in March warning of the ongoing risk of dengue infection.

“I think dengue is here with us to stay,” said infectious disease specialist Michael Ben-Aderet, associate medical director of hospital epidemiology at Cedars-Sinai in Los Angeles, about dengue becoming a new normal in the U.S. “These mosquitoes aren't going anywhere.”

Dengue is endemic — a label health officials assign when diseases appear consistently in a region — in many warmer parts of the world, including Latin America, India, and Southeast Asia. Dengue cases increased markedly last year in many of those places, especially in Central and South America.

The disease, which can spread when people are bitten by infected Aedes mosquitoes, was not common in the contiguous United States for much of the last century. Today, most locally acquired (meaning unrelated to travel) dengue cases in the U.S. happen in Puerto Rico, which saw a sharp increase in 2024, triggering a local public health emergency.

Most people who contract dengue don’t get sick. But in some people symptoms are severe: bleeding from the nose or mouth, intense stomach pain, vomiting, and swelling. Occasionally, dengue causes death.

California offers a case study in how dengue is spreading in the U.S. The Aedes aegypti and Aedes albopictus mosquitoes that transmit dengue weren’t known to be in the state 25 years ago. They are now found in 25 counties and more than 400 cities and unincorporated communities, mostly in Southern California and the Central Valley.

The spread of the mosquitoes is concerning because their presence increases the likelihood of disease transmission, said Steve Abshier, president of the Mosquito and Vector Control Association of California.

From 2016 through 2022, there were an average of 136 new dengue cases a year in California, each case most likely brought to the state by someone who had traveled and been infected elsewhere. In 2023, there were about 250 new cases, including two acquired locally.

In 2024, California saw 725 new dengue cases, including 18 acquired locally, state data shows.

Climate change could contribute to growth in the Aedes mosquitoes’ population, Ben-Aderet said. These mosquitoes survive best in warm urban areas, often biting during the daytime. Locally acquired infections often occur when someone catches dengue during travel, then comes home and is bitten by an Aedes mosquito that bites and infects another person.

“They've just been spreading like wildfire throughout California,” Ben-Aderet said.

Dengue presents a challenge to the many primary care doctors who have never seen it. Ben-Aderet said doctors who suspect dengue should obtain a detailed travel history from their patients, but confirming the diagnosis is not always quick.

“There's no easy test for it,” he said. “The only test that we have for dengue is antibody tests.” He added that “most labs probably aren't doing it commercially, so it's usually like a send-out test from most labs. So you really have to suspect someone has dengue.”

Best practices for avoiding dengue include eliminating any standing pools of water on a property — even small pools — and using mosquito repellent, Abshier said. Limiting activity at dusk and dawn, when mosquitoes bite most often, can also help.

Efforts to combat dengue in California became even more complicated this year after wildfires ripped through Los Angeles. The fires occurred in a hot spot for mosquito-borne illnesses. San Gabriel Valley Mosquito and Vector Control District officials have worked for months to treat more than 1,400 unmaintained swimming pools left in the wake of fire, removing potential breeding grounds for mosquitoes.

San Gabriel vector control officials have used local and state resources to treat the pools, said district spokesperson Anais Medina Diaz. They have applied for reimbursement from the Federal Emergency Management Agency, which has not historically paid for vector control efforts following wildfires.

In California, vector control agencies are often primarily funded by local taxes and fees on property owners.

Some officials are pursuing the novel method of releasing sterilized Aedes mosquitoes to reduce the problem. That may prove effective, but deploying the method in a large number of areas would be costly and would require a massive effort at the state level, Abshier said. Meanwhile, the federal government is pulling back on interventions: Several outlets have reported that the National Institutes of Health will stop funding new climate change-related research, which could include work on dengue.

This year, reported rates of dengue in much of the Americas have declined significantly from 2024. But the trend in the United States likely won’t be clear until later in the year, after the summer mosquito season ends.

Health and vector control researchers aren't sure how bad it will get in California. Some say there may be limited outbreaks, while others predict dengue could get much worse. Sujan Shresta, a professor and infectious disease researcher at the La Jolla Institute for Immunology, said other places, like Nepal, experienced relatively few cases of dengue in the recent past but now regularly see large outbreaks.

There is a vaccine for children, but it faces discontinuation from a lack of global demand. Two other dengue vaccines are unavailable in the United States. Shresta’s lab is hard at work on an effective, safe vaccine for dengue. She hopes to release results from animal testing in a year or so; if the results are positive, human trials could be possible in about two years.

“If there's no good vaccine, no good antivirals, this will be a dengue-endemic country,” she said.

Phillip Reese is a data reporting specialist and an associate professor of journalism at California State University-Sacramento.

This article was produced by KFF Health News, which publishes California Healthline, an editorially independent service of the California Health Care Foundation. 

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

USE OUR CONTENT

This story can be republished for free (details).

3 months 4 weeks ago

california, Multimedia, Public Health, States, Environmental Health, Florida, texas

Health

Can you afford to get sick?

Take a moment and think of how many persons you know; family, friends, co-workers, who have been affected by cancer, heart disease, stroke, or another critical illness. For many Jamaicans, it’s more than just a statistic. It’s personal. When...

Take a moment and think of how many persons you know; family, friends, co-workers, who have been affected by cancer, heart disease, stroke, or another critical illness. For many Jamaicans, it’s more than just a statistic. It’s personal. When...

3 months 4 weeks ago

Health

Could your gut health be why you are tired, moody and struggling to lose weight?

GUT HEALTH is crucial for overall well-being because it impacts digestion, immunity, mental health, and even heart health. A healthy gut ensures efficient nutrient absorption, strengthens the immune system, and may even influence mood and cognitive...

GUT HEALTH is crucial for overall well-being because it impacts digestion, immunity, mental health, and even heart health. A healthy gut ensures efficient nutrient absorption, strengthens the immune system, and may even influence mood and cognitive...

3 months 4 weeks ago

Health

Foods, habits that can nourish or harm your gut health

GUT HEALTH is an easy thing to take for granted or to ignore completely, if everything is generally functioning well. However, poor gut health can impact your overall health in a variety of ways, from the obvious stomach discomfort to less obvious...

GUT HEALTH is an easy thing to take for granted or to ignore completely, if everything is generally functioning well. However, poor gut health can impact your overall health in a variety of ways, from the obvious stomach discomfort to less obvious...

3 months 4 weeks ago

Health

The way forward for the Jamaican psilocybin industry

As awareness of psilocybin treating mental and behavioural conditions gathers steam in Jamaica, consultant psychiatrist Saphire Longmore is of the view that the positive turnarounds experienced by users of the ‘magic mushroom’ needs to be built...

As awareness of psilocybin treating mental and behavioural conditions gathers steam in Jamaica, consultant psychiatrist Saphire Longmore is of the view that the positive turnarounds experienced by users of the ‘magic mushroom’ needs to be built...

3 months 4 weeks ago

Health

The hidden cost of ignoring STI symptoms

Sexually transmitted infections (STIs) continue to be one of the most pressing yet under-addressed public health concerns in Jamaica. While progress has been made in education and awareness, far too many people still avoid getting tested, often...

Sexually transmitted infections (STIs) continue to be one of the most pressing yet under-addressed public health concerns in Jamaica. While progress has been made in education and awareness, far too many people still avoid getting tested, often...

3 months 4 weeks ago

Health – Dominican Today

Vice President denies financial crisis at SeNaSa

Santo Domingo.- Vice President Raquel Peña dismissed claims that the National Health Insurance (SeNaSa) is facing a financial crisis, responding to concerns raised by the opposition party Fuerza del Pueblo and the Dominican Medical Association.

Santo Domingo.- Vice President Raquel Peña dismissed claims that the National Health Insurance (SeNaSa) is facing a financial crisis, responding to concerns raised by the opposition party Fuerza del Pueblo and the Dominican Medical Association.

Peña emphasized that SeNaSa’s finances are stable and that the government continues to support the institution. She cited President Luis Abinader’s recent remarks, stating that while more resources may be needed, there is no crisis. She also noted that nearly two million people have joined the system under the current administration, reflecting progress toward universal healthcare.

Her remarks came during the reopening of the Fencing Pavilion at the Juan Pablo Duarte Olympic Center.

The opposition, however, claims SeNaSa has suffered a decline in management and finances, citing a rise in provider debt from 0.97% in 2020 to 44% in 2024, along with delays in medical services and operational issues. SeNaSa has yet to respond publicly to these accusations.

3 months 4 weeks ago

Health

Health | NOW Grenada

A dichotomy of emotions on 1 July

“I knew with the coming of the 2025 Hurricane Season, anxiety levels will again peak and the memories, triggers and weather forecast will cause the resurgence of untreated emotional and mental trauma”

3 months 4 weeks ago

Carriacou & Petite Martinique, Community, Environment, Health, OPINION/COMMENTARY, Weather, canada day, hurricane beryl, neals chitan

STAT

STAT+: Pharmalittle: We’re reading about Novo’s Wegovy launch gaffes, a former Pfizer exec’s subpoena, and more

Top of the morning to you. And a steamy one, it is. In fact, there is more steam rising from the grounds of the Pharmalot campus than from our ritual cup of stimulation; our choice today is marshmallow magic, by the way. But this is to be expected at this time of year, yes? In any event, there is work to be done, so as always, we have assembled a few items of interest for you.

After all, the world keeps spinning no matter what the thermometer says. Hope you have a successful day and conquer the world. And of course, do keep in touch. …

Novo Nordisk’s top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly entered the market, Reuters reports. Novo has enjoyed $46 billion in net profits since 2021, when Wegovy became the first highly effective obesity treatment approved in the U.S. But Lilly’s Zepbound therapy outstripped Wegovy in weekly new prescriptions this year as Novo struggles to convince investors it can remain competitive amid the weight loss drug boom. Novo is reorganizing its leadership team following the surprise ouster of chief executive office Lars Fruergaard Jorgensen. Other key executives already stepped down, including U.S. chief Doug Langa, who had insisted on a commercial launch soon after Wegovy’s U.S. approval. In heated internal discussions, sales and marketing executives urged Langa to first secure more supply and health insurance coverage, without which many patients could not afford Wegovy’s monthly cost of up to $1,300. Lilly was not expected to enter the market for at least two years and Novo could have been better prepared, according to former employees.

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an allegation that clinical testing related to the development of the company’s Covid-19 vaccine was purposefully delayed until after the 2020 presidential election, CNN reports. The demand for documents and a deposition from Philip Dormitzer comes after the committee says he failed to comply with requests to appear voluntarily and turn over records. Dormitzer is a key figure in the legislative probe. The committee has alleged it had information that the former Pfizer executive, after he left for a job with GSK, told his colleagues that Pfizer had delayed announcing its Covid vaccine was effective until after the election. The Wall Street Journal had reported that GSK brought those claims to federal prosecutors in Manhattan. But Dormitzer disputed that there had been any delay in seeking approval for the vaccine.

Continue to STAT+ to read the full story…

3 months 4 weeks ago

Pharma, Pharmalot, pharmalittle, STAT+

PAHO/WHO | Pan American Health Organization

OPS y SEGIB refuerzan su alianza para una Iberoamérica más saludable e inclusiva 

PAHO and SEGIB strengthen their partnership for a healthier and more inclusive Ibero-America

Cristina Mitchell

30 Jun 2025

PAHO and SEGIB strengthen their partnership for a healthier and more inclusive Ibero-America

Cristina Mitchell

30 Jun 2025

3 months 4 weeks ago

MedCity News

AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline

AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase 1 test as a potential treatment for B cell-mediated autoimmune disorders.

The post AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline appeared first on MedCity News.

3 months 4 weeks ago

BioPharma, Pharma, AbbVie, autoimmune disease, CAR-T, cell theapy, Clinical Trials, immunology, inflammation

Health | NOW Grenada

Farmers and Extension Officers: Grenada’s unsung heroes

In recognition of Nutrition Week 2025, the GFNC celebrated the vital role farmers and their dedicated extension officers play in strengthening Grenada’s food systems

3 months 4 weeks ago

Agriculture/Fisheries, Health, PRESS RELEASE, extension officer, farmer, gfnc, grenada food and nutrition council, nutrition week

Health | NOW Grenada

CARPHA and OECS commit to empowering men to prioritise wellness and longevity

“Men’s Health Month is a critical reminder that prevention saves lives, so note to self: regular check-ups, healthy habits, and early screenings are not just acts of self-care; they are acts of strength”

3 months 4 weeks ago

Health, PRESS RELEASE, cardiovascular disease, caribbean public health agency, carpha, cvd, lisa indar, men’s health month, NCDs, noncommunicable diseases, oecs, organisation of eastern caribbean states, paho, pan american health organisation

Pages